# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### **SCHEDULE 13D**

**Under the Securities Exchange Act of 1934** 

(Amendment No. 6)\*

**Alzamend Neuro, Inc.** 

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

02262M605

(CUSIP Number)

MILTON C. AULT, III c/o HYPERSCALE DATA, INC. 11411 SOUTHERN, HIGHLANDS PARKWAY, SUITE 190 Las Vegas, NV, 89141 (949) 444-5464

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/23/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

### **SCHEDULE 13D**

**CUSIP No.** 02262M605

1	Name of reporting person
•	MILTON C. AULT, III
	Check the appropriate box if a member of a Group (See Instructions)
2	<ul><li>✓ (a)</li><li>□ (b)</li></ul>
3	SEC use only
4	Source of funds (See Instructions)
4	AF, OO

5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6	Citizenship or place of organization UNITED STATES	
Number	7	Sole Voting Power 1,843.00
of Shares Benefici ally	8	Shared Voting Power 704,479.00
Owned by Each Reporti ng	9	Sole Dispositive Power 1,843.00
Person With:	10	Shared Dispositive Power 704,479.00
11	Aggregate amount beneficially owned by each reporting person 706,322.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
13	Percent of class represented by amount in Row (11) 18.5 %	
14	Type of Reporting Person (See Instructions) IN	

### **Comment for Type of Reporting Person:**

Sole voting and dispositive power represents shares of Common Stock. Shared voting and dispositive power represents (i) 6 61,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (ii) 23, 334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, (iii) 8,260 shares of Common Stock held by Ault Lending, LLC, (iv) 11,068 shares of Common Stock held by Ault Life Sciences, Inc., (v) 61 shares of Common Stock held by Ault Life Sciences Fund, LLC, and (vi) 12 shares of Common Stock underlying currently exercisable warrants held by Hyperscale Data, Inc. Excludes 2,470 shares of Common Stock underlying warrants held by Ault Lending, L LC that are not currently exercisable due to a beneficial ownership blocker limitation provision contained therein.

CUSIP No.
-----------

1	Name of reporting person
-	WILLIAM B. HORNE
	Check the appropriate box if a member of a Group (See Instructions)
2	<ul><li>✓ (a)</li><li>□ (b)</li></ul>
3	SEC use only
4	Source of funds (See Instructions)
4	00
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	

6	Citizenship or place of organization UNITED STATES	
Number of Shares Benefici ally Owned	7	Sole Voting Power 3,518.00
	8	Shared Voting Power 0.00
by Each Reporti ng Person	9	Sole Dispositive Power 3,518.00
With:	10	Shared Dispositive Power 0.00
11	<b>Aggregate</b> 3,518.00	e amount beneficially owned by each reporting person
12	Check if t	he aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent o	f class represented by amount in Row (11)
14	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person:
Represents (i) 3,333 shares of Common Stock and (ii) 185 shares of Common Stock underlying stock options currently exerci sable or exercisable within 60 days.

# **SCHEDULE 13D**

**CUSIP** No. 02262M605

	T
1	Name of reporting person
-	HENRY C.W. NISSER
	Check the appropriate box if a member of a Group (See Instructions)
2	<ul><li>✓ (a)</li><li>□ (b)</li></ul>
3	SEC use only
4	Source of funds (See Instructions)
4	00
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	
	Citizenship or place of organization
6	SWEDEN

	7	Sole Voting Power	
Number		926.00	
of Shares Benefici	8	Shared Voting Power	
ally Owned	8	0.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person	9	926.00	
With:	10	Shared Dispositive Power	
	10	0.00	
11	Aggregate amount beneficially owned by each reporting person		
	926.00		
40	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
12			
40	Percent of class represented by amount in Row (11)		
13	0.0 %		
14	Type of Reporting Person (See Instructions)		
14	IN		

Comment for Type of Reporting Person:
Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

02262M605
-----------

1	Name of reporting person
	KENNETH S. CRAGUN
	Check the appropriate box if a member of a Group (See Instructions)
2	
	(b)
3	SEC use only
4	Source of funds (See Instructions)
4	00
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	
	Citizenship or place of organization
6	UNITED STATES
4	

	7	Sole Voting Power	
Number		1,111.00	
of Shares Benefici	8	Shared Voting Power	
ally Owned	8	0.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person	9	1,111.00	
With:	10	Shared Dispositive Power	
	10	0.00	
	Aggregate amount beneficially owned by each reporting person		
11	1,111.00		
40	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
12			
40	Percent of class represented by amount in Row (11)		
13	0.0 %		
14	Type of Reporting Person (See Instructions)		
14	IN		

Comment for Type of Reporting Person:
Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

02262M605
-----------

	Name of reporting person
1	DAVID J. KATZOFF
2	Check the appropriate box if a member of a Group (See Instructions)  (a) (b)
3	SEC use only
4	Source of funds (See Instructions) PF, OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization UNITED STATES

	7	Sole Voting Power	
Number		1,726.00	
of Shares		Shared Voting Power	
Benefici ally Owned	8	0.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person	9	1,726.00	
With:	10	Shared Dispositive Power	
	10	0.00	
Aggregate amount beneficia		e amount beneficially owned by each reporting person	
11	1,726.00		
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		he aggregate amount in Row (11) excludes certain shares (See Instructions)	
12			
40	Percent of class represented by amount in Row (11)		
13	0.1 %		
14	Type of Reporting Person (See Instructions)		
14	IN		

Comment for Type of Reporting Person:
Represents (i) 615 shares of Common Stock and (ii) 1,111 shares of Common Stock underlying stock options currently exerci sable or exercisable within 60 days.

CUSIP No.	02262M605		
-----------	-----------	--	--

1	Name of reporting person
	HYPERSCALE DATA, INC.
	Check the appropriate box if a member of a Group (See Instructions)
2	<ul><li>✓ (a)</li><li>□ (b)</li></ul>
3	SEC use only
4	Source of funds (See Instructions)
4	AF
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	
6	Citizenship or place of organization
0	DELAWARE

	7	Sole Voting Power	
Number		0.00	
of Shares	8	Shared Voting Power	
Benefici ally Owned		693,349.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person	9	0.00	
With:	10	Shared Dispositive Power	
	10	693,349.00	
	Aggregate amount beneficially owned by each reporting person		
11	693,349.00		
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		he aggregate amount in Row (11) excludes certain shares (See Instructions)	
12			
42	Percent of class represented by amount in Row (11)		
13	18.1 %		
14	Type of Reporting Person (See Instructions)		
14	co		

Comment for Type of Reporting Person:
Represents (i) 12 shares of Common Stock underlying currently exercisable warrants held by it, (ii) 661,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (iii) 23,334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, and (iv) 8,260 shares of Common Stock held by A ult Lending, LLC. Excludes 2,470 shares of Common Stock underlying warrants held by Ault Lending, LLC that are not curre ntly exercisable due to a beneficial ownership blocker limitation provision contained therein.

CUSIP No.	02262M605		
-----------	-----------	--	--

1	Name of reporting person
	AULT LENDING, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	<ul><li>✓ (a)</li><li>✓ (b)</li></ul>
3	SEC use only
4	Source of funds (See Instructions)
4	WC, 00
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	
6	Citizenship or place of organization
0	CALIFORNIA

	7	Sole Voting Power	
Number of		0.00	
Shares Benefici	8	Shared Voting Power	
ally Owned		693,337.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person	9	0.00	
With:	10	Shared Dispositive Power	
	10	693,337.00	
	Aggregate amount beneficially owned by each reporting person		
11	693,337.00		
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		he aggregate amount in Row (11) excludes certain shares (See Instructions)	
12			
40	Percent of class represented by amount in Row (11)		
13	18.1 %		
14	Type of Reporting Person (See Instructions)		
14	00		

Comment for Type of Reporting Person:
Represents (i) 8,260 shares of Common Stock, (ii) 661,743 shares of Common Stock underlying shares of Series B Convertib le Preferred Stock and (iii) 23,334 shares of Common Stock underlying currently exercisable warrants. Excludes 2,470 share s of Common Stock underlying warrants that are not currently exercisable due to a beneficial ownership blocker limitation pro vision contained therein.

CUSIP No.	02262M605
-----------	-----------

1	Name of reporting person AULT LIFE SCIENCES, INC.				
2	Check the appropriate box if a member of a Group (See Instructions)  (a) (b)				
3	SEC use only				
4	Source of funds (See Instructions) WC				
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)				
6	Citizenship or place of organization  DELAWARE				
	1				

	7	Sole Voting Power	
Number		0.00	
of Shares Benefici	8	Shared Voting Power	
ally Owned		11,068.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person	9	0.00	
With:	10	Shared Dispositive Power	
	10	11,068.00	
Aggregate amount beneficially owned by each reporting person		e amount beneficially owned by each reporting person	
11	11,068.00		
40	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
12			
40	Percent of class represented by amount in Row (11)		
13	0.4 %		
44	Type of Reporting Person (See Instructions)		
14	co		

CUSIP No.	02262M605
-----------	-----------

1	Name of reporting person AULT LIFE SCIENCES FUND, LLC		
2	Check the appropriate box if a member of a Group (See Instructions)  (a) (b)		
3	SEC use	only	
4	Source of funds (See Instructions) WC, OO		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
6	Citizenship or place of organization  DELAWARE		
Number	7	Sole Voting Power 0.00	
of Shares Benefici ally Owned	8	Shared Voting Power 61.00	
by Each Reporti ng Person With:	9	Sole Dispositive Power 0.00	
	10	Shared Dispositive Power 61.00	

11	Aggregate amount beneficially owned by each reporting person
	61.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11)
	0.0 %
14	Type of Reporting Person (See Instructions)
	00

### SCHEDULE 13D

### Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, par value \$0.0001 per share

(b) Name of Issuer:

Alzamend Neuro, Inc.

(c) Address of Issuer's Principal Executive Offices:

3500 LENOX RD. NE, SUITE 1500, Atlanta, GEORGIA, 30326.

### **Item 1 Comment:**

This Amendment No. 6 ("Amendment No. 6") amends the statement on Schedule 13D originally filed by the Reporting Pers ons on June 25, 2021, as amended (the "Schedule 13D"), and relates to the Common Stock of Alzamend Neuro, Inc. Exce pt as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported in the Schedule 13D. Unless otherwise indicated, each capitalized term used but not defined in this Amendment No. 6 shall have the meaning assigned to such term in the Schedule 13D.

### Item 2. Identity and Background

(a) Item 2(a) is hereby amended and restated in its entirety to read as follows:

This Schedule 13D is filed by:

- (i) Hyperscale Data, Inc. (f/k/a Ault Alliance, Inc.), a Delaware corporation ("Hyperscale Data"), with respect to the shares of Common Stock of the Issuer (the "Shares") beneficially owned by it and as the holder of all of the equity interests of Ault Lending, LLC ("Ault Lending");
- (ii) Ault Lending, LLC, a California limited liability company, with respect to the Shares beneficially owned by it;
- (iii) Ault Life Sciences, Inc., a Delaware corporation ("Ault Life Sciences"), with respect to the Shares beneficially owned by it;
- (iv) Ault Life Sciences Fund, LLC, a Delaware limited liability company ("Ault Life Sciences Fund"), with respect to the Shares ben eficially owned by it;
- (v) Milton C. Ault, III, as Director of the Issuer, Executive Chairman of Hyperscale Data, Chief Executive Officer and Director of Ault Life Sciences and Managing Member of Ault Life Sciences Fund;
- (vi) William B. Horne, Chairman of the Board of Directors of the Issuer, Chief Executive Officer and Director of Hyperscale Data, C hief Executive Officer of Ault Lending and Chief Financial Officer and Director of Ault Life Sciences;
- (vii) Henry C.W. Nisser, Executive Vice President, General Counsel and Director of the Issuer, President, General Counsel and Director of Hyperscale Data and President and Director of Ault Life Sciences;
- (viii) Kenneth S. Cragun, Senior Vice President of Finance of the Issuer, Chief Financial Officer of Hyperscale Data and Chief Accounting Officer of Ault Life Sciences; and
- (ix) David Katzoff, Chief Financial Officer of the Issuer and Manager of Ault Lending.

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Set forth on Exhibit 1 ann exed hereto ("Exhibit 1") is the name and present principal occupation or employment, principal business address and citizenship of the executive officers and directors of Hyperscale Data, Ault Lending, Ault Life Sciences and Ault Life Sciences Fund. To the be st of the Reporting Persons' knowledge, except as otherwise set forth herein, none of the persons listed in Exhibit 1 beneficially o wns any securities of the Issuer or is a party to any contract, agreement or understanding required to be disclosed herein.

**(b)** Item 2(b) is hereby amended and restated in its entirety to read as follows:

The principal business address of Messrs. Ault, Horne and Cragun is c/o Hyperscale Data, Inc., 11411 Southern Highlands Parkw ay, Suite 190, Las Vegas, Nevada 89141. The principal business address of Mr. Nisser is c/o Hyperscale Data, Inc., 122 E. 50th S treet, Suite 5000, New York, NY 10168. The principal business address of Mr. Katzoff is c/o Alzamend Neuro, Inc., 3480 Peachtre e Road NE, Second Floor, Suite 103, Atlanta, GA 30326. The principal business address of Hyperscale Data is 11411 Southern Highlands Parkway, Suite 190, Las Vegas, Nevada 89141. The principal business address of each of Ault Life Sciences, Ault Life Sciences Fund and Ault Lending is 940 South Coast Drive, Suite 200, Costa Mesa, CA 92626.

(c) Item 2(c) is hereby amended and restated in its entirety to read as follows:

The principal occupation of Mr. Ault is serving as the Executive Chairman of Hyperscale Data. The principal occupation of Mr. Hor ne is serving as the Chief Executive Officer of Hyperscale Data. The principal occupation of Mr. Nisser is serving as the President and General Counsel of Hyperscale Data. The principal occupation of Mr. Cragun is serving as the Chief Financial Officer of Hyperscale Data. The principal occupation of Mr. Katzoff is serving as the Chief Financial Officer of the Issuer.

(d) Item 2(d) is hereby amended and restated in its entirety to read as follows:

No Reporting Person nor any person listed in Exhibit 1 has, during the last five years, been convicted in a criminal proceeding (ex cluding traffic violations or similar misdemeanors).

(e) Item 2(e) is hereby amended and restated in its entirety to read as follows:

No Reporting Person nor any person listed in Exhibit 1 has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Item 2(f) is hereby amended and restated in its entirety to read as follows:

Hyperscale Data, Ault Life Sciences and Ault Life Sciences Fund are organized under the laws of the State of Delaware. Ault Lend ing is organized under the laws of the State of California. Messrs. Ault, Horne, Cragun and Katzoff are citizens of the United State s of America. Mr. Nisser is a citizen of Sweden. The citizenship of the persons listed in Exhibit 1 is set forth therein.

### Item 3. Source and Amount of Funds or Other Consideration

Item 3 is amended and restated in its entirety as follows: The securities of the Issuer purchased by each of Hyperscale Data, Ault Life Sciences Fund were purchased with working capital. The securities of the Issuer acquired by Ault Lend ing were acquired with working capital, except for 691 shares issued for marketing and brand development services provided by Hyperscale Data, its parent entity. The Shares purchased by Messrs. Ault, Horne and Katzoff were purchased with personal funds. The stock options owned by Messrs. Ault, Horne, Nisser, Cragun and Katzoff were awarded to them in their capacities as officers and/or directors of the Issuer. The aggregate purchase price of the warrants currently exercisable into 12 Shares owned directly by Ault Alliance is approximately \$0. The aggregate purchase price of the 11,068 Shares owned directly by Ault Life Sciences is ap proximately \$7,970. The aggregate purchase price of the 61 Shares owned directly by Ault Life Sciences Fund is approximately \$1 23,707. The aggregate purchase price of the 8,260 Shares and warrants currently exercisable (subject to beneficial ownership limitations contained therein) into 23,334 Shares owned directly by Ault Lending is approximately \$24,446,080, which includes market ing and brand development services valued at \$1.4 million. The aggregate purchase price of the approximate 1,535.24 shares of Series B convertible preferred stock (the "Series B Convertible Preferred Stock") and warrants to purchase 2,470 Shares (which war rants are not currently exercisable) owned directly by Ault Lending is approximately \$1,535,245. The aggregate purchase price of the 1,843 Shares owned directly by Mr. Ault is approximately \$1,179. The aggregate purchase price of the 3,333 Shares owned directly by Mr. Horne is approximately \$14,028. The aggregate purchase price of the 615 Shares owned directly by Mr. Katzoff is approximately \$53,374.

### Item 5. Interest in Securities of the Issuer

### (a) Item 5(a) is hereby amended and restated in its entirety as follows:

The aggregate percentage of Shares reported beneficially owned by the Reporting Person is based upon 3,139,861 Shares outstanding as of July 30, 2025, which is the total number of Shares outstanding as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 1, 2025.

As of the date hereof, Mr. Ault may be deemed to beneficially own 706,321 Shares, consisting of (i) 1,843 Shares held directly by h im, (ii) 661,743 Shares underlying shares of Series B Convertible Preferred Stock held by Ault Lending, (iii) 23,334 Shares underlying currently exercisable warrants held by Ault Lending, (iv) 8,260 Shares held by Ault Lending, (v) 11,068 Shares held by Ault Life Sciences, (vi) 61 Shares held by Ault Life Sciences Fund, and (vii) 12 Shares underlying currently exercisable warrants held by Hyperscale Data. Excludes 2,470 Shares underlying warrants held by Ault Lending that are not currently exercisable due to a ben eficial ownership blocker limitation provision contained therein. Mr. Ault may be deemed to beneficially own the Shares beneficially owned by Hyperscale Data, Ault Life Sciences, Ault Life Sciences Fund and Ault Lending by virtue of his relationships with such e ntities described in Item 2.

Percentage: Approximately 18.5%

As of the date hereof, Mr. Horne may be deemed to beneficially own 3,518 Shares, consisting of (i) 3,333 Shares held directly by h im and (ii) 185 Shares underlying stock options currently exercisable or exercisable within 60 days. Percentage: Approximately 0.1%

As of the date hereof, Mr. Nisser may be deemed to beneficially own 926 Shares, consisting of Shares underlying stock options cu rrently exercisable or exercisable within 60 days.

Percentage: Approximately 0.0%

As of the date hereof, Mr. Cragun may be deemed to beneficially own 1,111 Shares, consisting of Shares underlying stock options currently exercisable or exercisable within 60 days. Percentage: Approximately 0.0%

As of the date hereof, Hyperscale Data may be deemed to beneficially own 693,349 Shares, consisting of (i) 12 Shares underlying currently exercisable warrants held directly by it, (ii) 661,743 Shares underlying shares of Series B Convertible Preferred Stock held by Ault Lending, (iii) 23,334 Shares underlying currently exercisable warrants held by Ault Lending, and (iv) 8,260 Shares held by Ault Lending. Excludes 2,470 Shares underlying warrants held by Ault Lending that are not currently exercisable due to a beneficial ownership blocker limitation provision contained therein. Hyperscale Data may be deemed to beneficially own the Shares beneficially owned by Ault Lending by virtue of its relationship with such entity described in Item 2. Percentage: Approximately 18.1%

As of the date hereof, Ault Lending may be deemed to beneficially own 693,337 Shares, consisting of (i) 8,260 Shares held directly by it, (ii) 661,743 Shares underlying shares of Series B Convertible Preferred Stock held directly by it, and (iii) 23,334 Shares underlying currently exercisable warrants held directly by it. Excludes 2,470 Shares underlying warrants held directly by it that are not c urrently exercisable due to a beneficial ownership blocker limitation provision contained therein. Percentage: Approximately 18.1%

As of the date hereof, Ault Life Sciences may be deemed to beneficially own 11,068 Shares held directly by it. Percentage: Approximately 0.4%

As of the date hereof, Ault Life Sciences Fund may be deemed to beneficially own 61 Shares held directly by it. Percentage: Approximately 0.0%

### (b) Item 5(b) is hereby amended and restated in its entirety as follows:

- 1. Sole power to vote or direct vote: 1,843
- 2. Shared power to vote or direct vote: 704,479
- 3. Sole power to dispose or direct the disposition: 1,843
- 4. Shared power to dispose or direct the disposition: 704,479

- Mr. Horne:
  1. Sole power to vote or direct vote: 3,518
- 2. Shared power to vote or direct vote: 0
- 3. Sole power to dispose or direct the disposition: 3,518
- 4. Shared power to dispose or direct the disposition: 0

### Mr. Nisser:

- 1. Sole power to vote or direct vote: 926
- 2. Shared power to vote or direct vote: 0
- 3. Sole power to dispose or direct the disposition: 926
- 4. Shared power to dispose or direct the disposition: 0

### Mr. Cragun:

- 1. Sole power to vote or direct vote: 1,111
- 2. Shared power to vote or direct vote: 0
- 3. Sole power to dispose or direct the disposition: 1,111
- 4. Shared power to dispose or direct the disposition: 0

### Mr. Katzoff:

- 1. Sole power to vote or direct vote: 1,726
- 2. Shared power to vote or direct vote: 0
- 3. Sole power to dispose or direct the disposition: 1,726
- 4. Shared power to dispose or direct the disposition: 0

### Hyperscale Data:

- Sole power to vote or direct vote: 0
- 2. Shared power to vote or direct vote: 693,349
- 3. Sole power to dispose or direct the disposition: 0
- 4. Shared power to dispose or direct the disposition: 693,349

### Ault Lending:

- 1. Sole power to vote or direct vote: 0
  2. Shared power to vote or direct vote: 693,337
- 3. Sole power to dispose or direct the disposition: 0
- 4. Shared power to dispose or direct the disposition: 693,337

### Ault Life Sciences:

- 1. Sole power to vote or direct vote: 0
- 2. Shared power to vote or direct vote: 11,068
- 3. Sole power to dispose or direct the disposition: 0
- 4. Shared power to dispose or direct the disposition: 11,068

# Ault Life Sciences Fund:

- 1. Sole power to vote or direct vote: 0
- 2. Shared power to vote or direct vote: 61
- 3. Sole power to dispose or direct the disposition: 0
- 4. Shared power to dispose or direct the disposition: 61
- (c) Item 5(c) is amended and restated in its entirety as follows:

None of the Reporting Persons have engaged in any transactions in the Shares during the past 60 days except as set forth in Exhi bit 2 hereto.

### Item 7. Material to be Filed as Exhibits.

Exhibit 1 - Officers and Directors

Exhibit 2 - Transactions in the Securities of the Issuer During the Past 60 Days

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MILTON C. AULT, III

/s/ Milton C. Ault, III Signature:

Name/Title: Individual 08/01/2025 Date:

WILLIAM B. HORNE

Signature: /s/ William B. Horne

Name/Title: Individual Date: 08/01/2025

# HENRY C.W. NISSER

Signature: /s/ Henry C. Nisser

Name/Title: Individual Date: 08/01/2025

# KENNETH S. CRAGUN

Signature: /s/ Kenneth S. Cragun

Name/Title: Individual Date: 08/01/2025

# DAVID J. KATZOFF

Signature: /s/ David J. Katzoff

Name/Title: Individual Date: 08/01/2025

# HYPERSCALE DATA, INC.

Signature: /s/ Milton C. Ault, III
Name/Title: Executive Chairman

Date: 08/01/2025

# **AULT LENDING, LLC**

Signature: /s/ David J. Katzoff

Name/Title: Manager
Date: 08/01/2025

# AULT LIFE SCIENCES, INC.

Signature: /s/ Milton C. Ault, III
Name/Title: Chief Executive Officer

Date: 08/01/2025

# AULT LIFE SCIENCES FUND, LLC

Signature: /s/ Milton C. Ault, III
Name/Title: Managing Member

Date: 08/01/2025

# Officers and Directors of Hyperscale Data, Inc.

Name and Position	Principal Occupation	Principal Business Address	Citizenship
Milton C. Ault, III Executive Chairman	Executive Chairman of Hyperscale Data, Inc.	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141	USA
William B. Horne Chief Executive Officer and Director	Chief Executive Officer of Hyperscale Data, Inc.	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141	USA
Henry C.W. Nisser President, General Counsel and Director	President and General Counsel of Hyperscale Data, Inc.	c/o Hyperscale Data, Inc. 122 E. 42 <sup>nd</sup> Street, Suite 5000, New York, NY 10168	Sweden
Kenneth Cragun Chief Financial Officer	Chief Financial Officer of Hyperscale Data, Inc.	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141	USA
Jeffrey A. Bentz Independent Director	Independent Consultant	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141	USA
Robert O. Smith Independent Director	Independent Executive Consultant	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141	USA
Moti Rosenberg Independent Director	Independent Consultant	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141	Israel

### Officers and Directors of Ault Life Sciences, Inc.

Name and Position	Principal Occupation	Principal Business Address	Citizenship	
Milton C. Ault, III	Executive Chairman of Hyperscale Data,	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite	USA	
Chief Executive Officer and Chairman	Inc.	190, Las Vegas, NV 89141	USA	
William B. Horne	Chief Executive Officer of Hyperscale	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite	USA	
Chief Financial Officer and Director	Data, Inc.	190, Las Vegas, NV 89141	USA	
Henry C.W. Nisser	President and General Counsel of	eral Counsel of c/o Hyperscale Data, Inc. 122 E. 42nd Street, Suite 5000, New York,		
President and Director	Hyperscale Data, Inc.	NY 10168	Sweden	
Kenneth Cragun	Chief Financial Officer of Hyperscale	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite	USA	
Chief Accounting Officer	Data, Inc.	190, Las Vegas, NV 89141	USA	

### $\underline{Officers\ and\ Directors\ of\ Ault\ Life\ Sciences\ Fund,\ LLC}$

Name and Position	Principal Occupation	<u>Principal Business Address</u>	<u>Citizenship</u>
Milton C. Ault, III	Executive Chairman of Hyperscale Data,	c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway, Suite	USA
Managing Member	Inc.	190, Las Vegas, NV 89141	USA

# Officers and Directors of Ault Lending, LLC

Name and Position	Principal Occupation	Principal Business Address	Citizenship	
David J. Katzoff	Chief Financial Officer of Alzamend	c/o Alzamend Neuro, Inc., 3480 Peachtree Road NE, Second Floor,	USA	
Manager	Neuro, Inc.	Suite 103, Atlanta, GA 30326	USA	
William B. Horne	Chief Executive Officer of Hyperscale c/o Hyperscale Data, Inc. 11411 Southern Highlands Parkway,		USA	
Chief Executive Officer	Data, Inc.	190. Las Vegas, NV 89141	USA	

# Ault Lending, LLC

# <u>Transactions in the Series B Convertible Preferred Stock Within the Last Sixty Days</u>

Nature of the Transaction	Shares of Series B Convertible Preferred Stock Purchased / (Sold)	Price Per Share (\$)	Date of Transaction
Conversion of Series B Convertible Preferred Stock into shares of Common			
Stock	332.75528	\$1,000.00	07/23/2025
Conversion of Series B Convertible			
Preferred Stock into shares of Common			
Stock	232	\$1,000.00	07/30/2025

# <u>Transactions in the Shares of Common Stock Within the Last Sixty Days</u>

	Shares of Common Stock		
Nature of the Transaction	Purchased / (Sold)	Price Per Share (\$)	Date of Transaction
Sale	(59,516)	2.9502	07/23/2025
Sale	(9,621)	2.9349	07/24/2025
Sale	(36,532)	2.8976	07/25/2025
Sale	(8,311)	2.6849	07/28/2025
Sale	(29,449)	2.5122	07/30/2025
Sale	(100,000)	2.2155	07/31/2025